With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...
Eli Lilly announces $15 billion share buyback plan and 15% dividend boost amidst mixed technical signals. Investors are ...
The company also raised its quarterly dividend 15% amid rapid growth fueled in part by the blockbuster weight-loss drug ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 512.66% and ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...
According to the announcement, the share repurchase program allows for flexibility in purchasing methods, including open ...
Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 billion stock repurchase plan ended in the fourth quarter of 2024.
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie ...
Weight-loss drugs could be a boon for insurers, but it is too soon to tell whether the industry will be transformed, the head ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) declared that its Board of Directors has approved a stock buyback program on Monday, December 9th, RTT News reports. The company plans to repurchase ...